Ocugen Outlines Three-Year FDA Roadmap as Gene Therapy Timelines Extend to 2028
核心洞察
Ocugen outlined timelines for three planned Biologics License Applications with the FDA, all targeting serious eye disorders with few adequate treatment options.
OCU400 for retinitis pigmentosa (搜索) is slated for top-line data in the first quarter of 2027, with a BLA submission to follow immediately.
OCU410ST for Stargardt disease (搜索) expects pivotal data in the second quarter of 2027, while OCU410 for geographic atrophy (搜索) in dry AMD files at the end of 2028.
Ocugen has laid out a detailed regulatory calendar for its gene therapy pipeline, covering three planned Biologics License Applications with the FDA, all aimed at serious eye disorders that currently have few adequate treatment options. The lead program, OCU400 for retinitis pigmentosa (搜索), is expected to generate top-line data in the first quarter of 2027, with the BLA submission to follow immediately. OCU410ST for Stargardt disease (搜索) is close behind, with pivotal data anticipated in the second quarter of 2027 and a filing intended right after. The third candidate, OCU410 for geographic atrophy (搜索) tied to dry age-related macular degeneration (搜索), will not see a filing until the end of 2028.
Ocugen also reaffirmed its commitment to the ongoing OCU410ST study. Following a review by an independent data monitoring committee, the company is continuing the trial as planned, and media reports indicate the full dataset will be awaited after a twelve-month follow-up period before final assessments are made. That approach follows an earlier interim analysis that had unsettled shareholders. For the more advanced OCU410 program, Ocugen holds the FDA's Regenerative Medicine Advanced Therapy designation.
With the regulatory horizon pushed out, attention shifts to incremental proof points. Ocugen will present randomized twelve-month Phase 2 results from the ArMaDa study of subretinal OCU410 in geographic atrophy (搜索) on Thursday, September 24, at the 59th annual meeting of the Retina Society.